Evolution of the Average Target: Moderna, Inc.

Evolution of the Target Price: Moderna, Inc.

Changes in Analyst Recommendations: Moderna, Inc.

d4f6e01edd33f5e4eb16063f1.WMInL2fnb50rd-U6aEMByG3ea2p8-yuIUG1p5hkaB_s.IIYTQUrKDsJoAr94OgFGkiO7ICdMiXTqGFkDtGhbS5Yzo05kEopeq1o4oA~633740effe27d01907b80a7d19088ef4
11:47am Goldman Sachs Adjusts Price Target on Moderna to $36 From $33, Maintains Neutral Rating MT
Jan. 07 UBS Downgrades Moderna to Neutral From Buy, Cuts Price Target to $34 From $40 MT
Jan. 06 BofA Adjusts Price Target on Moderna to $24 From $21, Maintains Underperform Rating MT
Dec. 12 Morgan Stanley Adjusts Moderna Price Target to $28 From $30, Maintains Equalweight Rating MT
Dec. 12 Jefferies Initiates Coverage on Moderna With Hold Rating, $30 Price Target MT
Nov. 26 Berenberg Trims Price Target on Moderna to $26 From $28, Keeps Hold Rating MT
Nov. 21 Piper Sandler Adjusts Price Target on Moderna to $63 From $69, Maintains Overweight Rating MT
Nov. 21 Leerink Partners Adjusts Price Target on Moderna to $18 From $15, Maintains Underperform Rating MT
Nov. 21 RBC Cuts Price Target on Moderna to $25 From $28, Keeps Sector Perform Rating MT
Nov. 21 Wolfe Research Adjusts Price Target on Moderna to $17 From $16, Maintains Underperform Rating MT
Nov. 21 Analyst recommendations: Block, Palo Alto Networks, Biogen, Moderna, Netflix… Zonebourse
Nov. 17 Berenberg Adjusts Price Target on Moderna to $28 From $30, Maintains Hold Rating MT
Nov. 11 Moderna's Cost-Cutting, Pipeline Catalysts Set Stage for 2026 Upside, UBS Says MT
Nov. 11 Rothschild & Co Redburn Adjusts Price Target on Moderna to $36 From $53, Maintains Neutral Rating MT
Nov. 07 Leerink Partners Adjusts Moderna Price Target to $15 From $12 MT
Nov. 07 Moderna Continues to Target Cash Breakeven in 2028, Morgan Stanley Says MT
Nov. 07 Barclays Adjusts Price Target on Moderna to $25 From $31, Maintains Equalweight Rating MT
Nov. 07 Goldman Sachs Adjusts Price Target on Moderna to $33 From $34, Maintains Neutral Rating MT
Nov. 07 America's markets lose their nerve Zonebourse
Nov. 07 Morgan Stanley Trims Price Target on Moderna to $30 From $32, Keeps Equalweight Rating MT
25-10-23 UBS Adjusts Price Target on Moderna to $40 From $70, Maintains Buy Rating MT
25-10-23 Moderna: Oddo BHF lowers target price Zonebourse
25-10-23 Leerink Partners Adjusts Price Target on Moderna to $12 From $16, Maintains Underperform Rating MT
25-10-23 Evercore ISI Adjusts Price Target on Moderna to $28 From $32, Maintains In Line Rating MT
25-10-23 Citigroup Adjusts Price Target on Moderna to $28 From $30, Maintains Neutral Rating MT
More recommendations

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+6.71%
+3.53%
+19.36%
+5.09%
+34.61%
+1.82%
-5.4%
+25.31%
+2.15%
+15.14%
Average +10.83%
Weighted average by Cap. +12.09%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
24
Last Close Price
34.30USD
Average target price
36.60USD
Spread / Average Target
+6.71%
High Price Target
135.00USD
Spread / Highest target
+293.59%
Low Price Target
17.00USD
Spread / Lowest Target
-50.44%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

UBS
BofA Securities
Morgan Stanley
Jefferies & Co.
Berenberg Bank
Piper Sandler
Leerink Partners
RBC Capital Markets
Wolfe Research
Rothschild & Co Redburn
Barclays
Goldman Sachs
Evercore ISI
Citigroup
Bernstein
JPMorgan Chase
DBS Bank
TD Cowen
Deutsche Bank Securities
Redburn Atlantic
HSBC
Argus
Baptista Research
BERENBERG Harry Gillis
Brookline Capital Markets
Oppenheimer
Oddo BHF
JPMORGAN Jessica Fye
RBC Luca Issi
Redburn
Canaccord Genuity
William Blair & Co.
Guggenheim
SVB Securities LLC
Cowen
Chardan Research
SVB Leerink
Chardan
J.P. Morgan Chase
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
24
Last Close Price
34.30USD
Average target price
36.60USD
Spread / Average Target
+6.71%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. MRNA Stock
  4. Consensus Moderna, Inc.